Progenity Inc. (NASDAQ: PROG) stock gained by 2.39% at last close while the PROG stock price surges by 4.67% in the pre-market trading session. Progenity, Inc. is a biotechnology firm that develops products for women’s health, gastrointestinal health, and oral biotherapeutics.

PROG stock’ Recent Development

The United States Patent and Trademark Office (USPTO) has granted Progenity four patents related to its ingestible technology for therapeutic administration via the gastrointestinal (GI) tract.

The United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,007,356 for an “ingestible device for administration of a therapeutic medicament to the gastrointestinal system.” Methods and equipment for delivering a therapeutic drug into gastrointestinal tissue for systemic uptake are covered by the patent. Progenity’s Oral Biotherapeutic Administration System (OBDS) is a comprehensive, needle-free delivery of bio-therapeutics through an ingestible device that is presently under development. So far, preclinical research has shown that the OBDS can achieve protein bioavailability of up to 44 percent.

The USPTO has also granted US Patent No. 11,033,490 for the use of a Janus kinase (JAK) inhibitor to treat inflammatory gastrointestinal disorders. The invention includes techniques for curing ulcerative colitis with an ingestible device that distributes a JAK inhibitor straight to the large intestine’s proximal portion. Progenity is gearing up to begin early clinical tests of its PGN-600 program for targeted therapy of a proprietary formulation of tofacitinib, a JAK inhibitor, to the spot of disease using Progenity’s Drug Delivery System (DDS), which is also in development, as part of its GI-targeted therapeutics program. The business conducted preclinical testing on PGN-600 earlier this year, showing at least 25 times more tofacitinib in colon tissue and less drug in blood than a typical oral dosage.

Furthermore,

U.S. Patent No. 11,134,889 for “Treatment of a gastrointestinal tract disease with a SMAD7 inhibitor” and U.S. Patent No. 10,980,739 for “Treatment of a gastrointestinal tract disease with a chemokine/chemokine receptor inhibitor has been granted by USTPO.” These patents are included in the company’s GI-targeted therapies portfolio, which comprises more than 170 issued and ongoing patents for 17 inflammatory bowel disease targets, notably TNF-alpha, IL-12/23, and integrins.